Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03535298 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Study acronym: DELIVER-MS
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description expanded, about 291 wordsv14
  2. Primary endpoints revised (2)
    • Study completion date: Sep 2030 to Jul 30, 2027
    • Secondary endpoints revised (7)
    v13
  3. Primary completion date: Apr 30, 2030 to Jul 30, 2027v12
  4. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 31 to 30
    v11
  5. Primary completion date: Dec 31, 2025 to Apr 30, 2030v10 Show 4 more changesShow less
    • Primary endpoints: 1 to 2
    • Study completion date: Sep 2026 to Sep 2030
    • Secondary endpoints: 4 to 7
    • Site contacts updated at 5 of 31 sites
Show 8 earlier versionsHide 8 earlier versions
  1. Study sites: 23 to 31v9
  2. Study sites: 22 to 23
    • Eligibility criteria expanded, about 8 words
    v8
  3. Primary completion date: Dec 31, 2022 to Dec 31, 2025
    • Study sites: 23 to 22
    • Study completion date: Sep 2023 to Sep 2026
    v7
  4. Site details revised at 11 of 23 sitesv6
  5. Study sites: 2 to 23v5
  6. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Sep 2022 to Dec 31, 2022
    • Start date changed from estimate of Oct 2018 to Jan 3, 2019
    • Site details revised at 2 of 2 sites
    v4
  7. Start date: Aug 2018 to Oct 2018
    • Primary completion date: Jul 2022 to Sep 2022
    • Study completion date: Jul 2023 to Sep 2023
    • Eligibility criteria expanded, about 5 words
    v3
  8. Secondary endpoints: details revised at 1 of 4 entries
    • Study title expanded, about 1 word
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties.
Trial Details
NCT Number NCT03535298
Lead Sponsor The Cleveland Clinic
Collaborators: University of Nottingham
Conditions
(from sponsor)		 Multiple Sclerosis, Relapsing-Remitting
Related terms Multiple Sclerosis, Relapsing-Remitting
Enrollment 800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov